The impact of the associated symptoms of other LUTS by tadalafil administration to patients with BPH

The impact of the associated symptoms of other LUTS by tadalafil administration to patients with BPH - The impact of the associated symptoms of other LUTS by tadalafil administration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020040

Enrollment

400

Registered

2015-12-03

Start date

2015-12-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Prostate volume, residual urine, IPSS, QOL score, OABSS, NIH Chronic Prostatitis Symptom Index (NIH-CPSI), and IIEF5 Questionnaire will be evaluated before and after additional administration and 4 we

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with diagnosed BPH More than 40 years old

Exclusion criteria

Exclusion criteria: 1. Patients with a history of hypersensitivity to components of tadalafil 2. Patients in the administration of nitrate agent or nitric oxide (NO) donating agent (nitroglycerin, amyl nitrite, nitrate Isozorubido) 3. Patients in the administration of soluble guanylate cyclase (sGC) stimulator (the Riociguat) 4. See the section of the patient ["Other notes" with the next listed cardiovascular system disorders. In addition, there is no experience for these patients. ] (1) patients with unstable angina (2)Patients with heart failure (NYHA classification 3 degrees or more) (3)Patients with uncontrolled arrhythmias, hypotension (blood pressure <90 / 50mmHg), or uncontrolled hypertension (resting blood pressure> 170 / 100mmHg) (4) Patients with a history of myocardial infarction is that within the last three months (5) Patients with a history of cerebral infarction, cerebral hemorrhage that is within the last 6 months 5. Patients with patients 6. severe liver failure 7. with severe renal failure 8. Other, patients attending physician has determined that inadequate

Design outcomes

Primary

Measure	Time frame
Prostate volume, residual urine, IPSS, QOL score, OABSS, NIH Chronic Prostatitis Symptom Index (NIH-CPSI), and IIEF5 Questionnaire will be evaluated before and after additional administration and 4 weeks. In the possible case, voiding diary is also evaluated before and after administration. Also, the side effects will be evaluated by interview	—

Countries

Japan

Contacts

Public ContactYASUHIRO YAMADA

Kyoto Prefecturral University of Medicine Urology

y-yamada@koto.kpu-m.ac.jp075-251-5595

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026